Company: GRCE
Filing Date: 2025-09-12
Form Type: 8-K
Source: 0001140361-25-034845
Chunk: 0

Company: Grace Therapeutics, Inc.
Filing Date: 2025-09-12
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07      Submission of Matters to a Vote of Security Holders.  

On September 12, 2025, Grace Therapeutics, Inc. (the “ Company”) held
its Annual Meeting of Stockholders (the “ Meeting”). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Company’s board of
director’s solicitation. Stockholders of a total of 7,926,945 of the Company’s shares of common stock were present or represented by proxy at the Meeting,
representing 57.32% of the Company’s 13,828,562 shares of common stock issued and outstanding and entitled to vote at the Meeting as of the record date of July
18, 2025. Set forth below are the matters acted upon by the Company’s stockholders at the Meeting and the final voting results on each matter. Each of the proposals is described in further detail in the Proxy Statement.

Proposal No. 1 - Election of Directors

The nominees listed below were elected as directors by the following votes to serve until the close of the Company’s next annual meeting of stockholders and until such
director’s successor is elected and qualified or until his earlier death, resignation, retirement, disqualification or removal:

  Nominee                 Votes For      Withheld      Broker Non-Votes  
  Nominee                 Votes For      Withheld      Broker Non-Votes  
 ─────────────────────────────────────────────────────────────────────────
  Vimal Kavuru            6,294,270        34,185             1,598,490  
  A. Brian Davis          6,299,935        28,520             1,598,490  
  Prashant Kohli          6,299,420        29,035             1,598,490  
  S. George Kottayil      6,300,168        28,287             1,598,490  
  Edward Neugeboren       6,300,263        28,192             1,598,490  

Proposal No. 2 - Advisory Vote to Approve Named Executive Officer Compensation

The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement was approved by the
stockholders by the following vote:

        For      Against      Abst